Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC1 | Q13547 | 2/20 | 0.60 |
| ▸ | NAMPT | P43490 | 1/20 | 0.58 |
| ▸ | EPHX2 | P34913 | 9/20 | 0.55 |
| ▸ | NR1H4 | Q96RI1 | 7/20 | 0.55 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.52 |
| ▸ | RAB9A | P51151 | 2/20 | 0.51 |
| ▸ | LMNA | P02545 | 1/20 | 0.51 |
| ▸ | MAPT | P10636 | 2/20 | 0.50 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.50 |
| ▸ | MEN1 | O00255 | 2/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.50 |
| ▸ | NPC1 | O15118 | 1/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.50 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.50 |
| ▸ | SLC22A6 | Q4U2R8 | 1/20 | 0.50 |
| ▸ | SLC22A8 | Q8TCC7 | 1/20 | 0.50 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.50 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.50 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.49 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1668544 | 0.87 | NR1H4 (0.76) | HDAC1NAMPTEPHX2NR1H4L3MBTL1 | |
| SCHEMBL6622954 | 0.87 | NAMPT (0.59) | HDAC1NAMPTEPHX2NR1H4L3MBTL1 | |
| SCHEMBL22291745 | 0.85 | EPHX2 (0.64) | HDAC1NAMPTEPHX2NR1H4L3MBTL1 | |
| SCHEMBL8203403 | 0.85 | NAMPT (0.54) | HDAC1NAMPTEPHX2NR1H4L3MBTL1 | |
| SCHEMBL2507542 | 0.85 | NAMPT (0.60) | HDAC1NAMPTEPHX2NR1H4L3MBTL1 | |
| SCHEMBL133327 | 0.85 | KMT2A (0.60) | HDAC1NAMPTEPHX2NR1H4L3MBTL1 | |
| SCHEMBL3180689 | 0.84 | L3MBTL1 (0.61) | HDAC1NAMPTL3MBTL1MAPTHDAC6 | |
| SCHEMBL9221746 | 0.84 | NAMPT (0.57) | HDAC1NAMPTEPHX2NR1H4L3MBTL1 | |
| SCHEMBL26032300 | 0.84 | MEN1 (0.57) | HDAC1NAMPTEPHX2NR1H4L3MBTL1 | |
| SCHEMBL8592267 | 0.84 | NAMPT (0.57) | HDAC1NAMPTEPHX2NR1H4L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7141570-B2 | N-aryl-2-oxazolidinone-5-carboxamides and their derivatives | PHARMACIA & UPJOHN COMPANY (US) | 2006-11-28 | — | — | US | disclosed |
| EP-1565186-B1 | N-(4-(PIPERAZIN-1-YL)-PHENYL-2-OXAZOLIDINONE-5-CARBOXAMIDE DERIVATES AND RELATED COMPOUNDS AS ANTIBACTERIAL AGENTS | PHARMACIA & UPJOHN CO LLC (US) | 2006-11-02 | — | — | EP | disclosed |
| EP-1565186-A1 | N-(4-(PIPERAZIN-1-YL)-PHENYL-2-OXAZOLIDINONE-5-CARBOXAMIDE DERIVATES AND RELATED COMPOUNDS AS ANTIBACTERIAL AGENTS | Pharmacia & Upjohn Company LLC (US) | 2005-08-24 | — | — | EP | disclosed |
| US-20040142939-A1 | N-Aryl-2-oxazolidinone-5-carboxamides and their derivatives | PHARMACIA & UPJOHN COMPANY | 2004-07-22 | — | — | US | disclosed |
| WO-2004045616-A1 | N-(4-(PIPERAZIN-1-YL)-PHENYL-2-OXAZOLIDINONE-5-CARBOXAMIDE DERIVATES AND RELATED COMPOUNDS AS ANTIBACTERIAL AGENTS | PHARMACIA & UPJOHN COMPANY LLC (US) | 2004-06-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040142939-A1 | N-Aryl-2-oxazolidinone-5-carboxamides and their derivatives | OXA1L, AADAC, MT-ND5 | HDAC1 34/4885NAMPT 434/4885EPHX2 4330/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.